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Antonio Rodrı´guez Perez1The gastrointestinal (GI) tract is the main target site of graft-versus-host disease (GVHD). Diagnosis is based
on endoscopic and histological findings. Helicobacter pylori (HP) is a Gram-negative spiral bacterium linked to
gastritis, peptic ulcer disease, gastric mucosa–associated lymphoid tissue lymphoma, and adenocarcinoma
and is frequently observed on endoscopy in patients who have undergone transplantation. The role, if any,
played by HP infection in the development of acute GVHD is unknown.We conducted a retrospective study
between January 1, 1990, and December 31, 2008, of 338 upper GI endoscopies (gastroscopies) performed
on patients who underwent allogeneic stem cell transplantation with clinical suspicion of GVHD (198
patients). Acute and chronic GVHD were confirmed from histological features in 97 patients (51.3%) and
68 patients (36%), respectively. HP infection was detected in 69 patients (35%) and had a negative modulating
effect on the development of acute GVHD (relative risk [RR], 0.60; 95% confidence interval, 0.46-0.79; P5
.001) and chronic GVHD (RR, 0.75; 95% confidence interval, 0.61-0.92; P5.016). Furthermore, the presence
of HP was inversely correlated with the histological severity of GVHD (P 5 .003). Our findings suggest that
infection with HP may have a negative modulating effect on GVHD.
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Allogeneic stem cell transplantation is the best
therapeutic option for many patients with hematologic
malignancies, although it is associated with significant
morbidity and mortality, due mostly to graft-versus-
host disease (GVHD) [1]. Acute gastrointestinal (GI)
GVHD presents as nausea, anorexia, vomiting, diar-
rhea, abdominal pain, hemorrhage, and ileus, and
carries a .80% risk of mortality in severe forms [2].
The GI tract is also a target organ for chronic GVHD,
clinical manifestations of which include anorexia,
nausea, vomiting, diarrhea, weight loss, esophageal1Department of Gastroenterology; 2Hematology; and
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insufficiency [3].
Due to the frequencyofGI symptomsduring thefirst
100 days after hematopoietic stem cell transplantation
(HSCT), more than 50% of patients are referred for an
endoscopic evaluation of the enteric tract. Differential
diagnosis of GVHD and other conditions, such as toxic-
ity from chemotherapy or radiotherapy, drug-related
adverse effects, and bacterial, viral, parasitic, or fungal
infections, should be performed [4,5]. Endoscopic
evidence of GVHD in the stomach and duodenum may
range from normal mucosa to nonspecific signs such
as edema, erythema, frank ulcers, and erosion of the
mucosa [6].
Helicobacter pylori (HP) is a Gram-negative bacillus
that has been linked to several digestive disorders, in-
cluding gastric cancer and mucosa-associated lym-
phoid tissue lymphoma. HP infection has coexisted
with the human species for more than 50,000 years
[7,8]. The infection is acquired during childhood and,
if untreated, remains present in the body throughout
the lifespan, although it causes symptoms in only
a subset of patients [9,10]. The prevalence of HP
infection is related to age, socioeconomic class, and
country of origin, varying between 20% and 30% in
developed countries and between 60% and 80% in765
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Humans are the primary reservoir, and several trans-
mission methods have been proposed, including
oral-oral, waterborne transmission, fecal-oral, and
gastro-oral [12].ChronicHP infection can produce en-
doscopic findings similar to those seen in stage I and II
GVHD, and histological analysis may reveal apoptotic
bodies [13,14]. Mucosal biopsy and histological
examination of specimens for the presence of HP is
the diagnostic method of choice for patients in whom
an endoscopy is clinically indicated, with a sensitivity
of 100%, a specificity of 66%, and positive and
negative predictive values of 84% and 100%,
respectively [15].
We conducted a retrospective study in patients
with GI symptoms after allogeneic HSCT referred
for an endoscopy to the GastroenterologyDepartment
to establish the diagnosis of GVHD and assess the
presence of HP infection, as well as any association
of this infection with the development and severity of
GVHD.MATERIALS AND METHODS
We performed a retrospective study on all of the
patients who underwent allogeneic HSCT at the Uni-
versity Hospital of Salamanca between January 1,
1990, and December 31, 2008, and who were referred
to our department for an upper GI endoscopy due to
suspected GVHD. Patient and donor characteristics
are summarized in Table 1. The graft sources were
not manipulated, and there were no mismatched do-
nors. All patients received bacterial prophylaxis with
meropenem during the period of neutropenia, and
omeprazole was administered until engraftment and
achievement of adequate oral intake. The endoscopic
findings from these explorations, histological findings
of the biopsies (a minimum of 3 biopsies) performed
during the procedure, and the presence of HP were
retrospectively compiled. One pathologist involved
in allogeneic HSCT for 15 years reviewed all of the
samples. Standard hematoxylin and eosin was the stain
used in all cases. The presence of apoptotic bodies in
the biopsy specimen (minimum criterion), crypt ab-
scesses, and/or destruction of glands were considered
criteria for a diagnosis of acute or chronic GVHD, af-
ter ruling out other causes that also could induce these
findings, such as drug-related toxicity or infections by
blood and/or stool cultures, cytomegalovirus infection
by antigenemia assay, or a reduced dose of the suspect
drug.
Twenty-six patients required two endoscopies to
confirm or rule out acute GVHD in the first 100
days post-HSCT. For these patients, we included the
endoscopy in which the endoscopic and histological
features were of a higher grade. Endoscopic findings
were staged according to the classification systemproposed by Cruz-Correa et al. [16]: stage 0, normal;
stage I, loss of vascular pattern and/or focal moderate
erythema; stage II, edema and/or diffuse moderate
erythema; stage III, edema, erythema, erosions, and/
or bleeding; stage IV, ulceration, exudates, and/or
bleeding.
In the histological analysis, the presence of apopto-
tic bodies was considered ‘‘compatible with GVHD.’’
The histological findings were staged according to
the classification system proposed by McDonald and
Sale [17] in 1984: grade 0, normal; grade I, single cell
necrosis (apoptosis) noted undermedium power; grade
II, evidence of epithelial damage by crypt/gland ab-
scesses, epithelial flattening, or crypt/gland dilations;
grade III, dropout of one or more crypt/gland; grade
IV, total epithelial denudation.
A diagnosis of HP infection was confirmed if the
bacterium was detected in the biopsy specimen from
the gastric antrum.
In the statistical analyses, performed with SPSS
version 15.0 (SPSS, Chicago, IL), percentages were
used for categorical variables, and measures of central
tendency (mean and/or median) and dispersion (stan-
dard deviation) were used for continuous variables.
All dichotomous variables were analyzed with c2
contingency tests to compare the frequencies of of
categorical variables or, where appropriate, Fisher’s
exact test and Monte Carlo simulations, and 95%
confidence intervals (CIs) for odds ratios (ORs) were
derived. Continuous and categorical variables were
analyzed by analysis of variance. Multivariate logistic
regression was used to analyze confounding factors.
Statistical significance was set at P\ .05.RESULTS
Baseline characteristics of the study group are
summarized in Tables 1 and 2. HP infection was
detected in 69 patients (35%). The incidence of HP
was significantly lower in patients with acute GVHD
than in those without acute GVHD (15.5% vs 38%;
relative risk [RR], 0.58; 95% CI, 0.44-0.76; P\. 001)
(Figure 1). The association was confirmed by logistic
regression adjusted for sex, age, donor type, progenitor
cell source, sex mismatch, and type of conditioning
regimen (OR, 2.87; 95% CI, 1.33-6.16; P 5 .007), as
well as for GVHD prophylaxis (OR, 2.64; 95% CI,
1.25-5.55; P 5 .010).
Similarly, the incidence of HP was lower in pa-
tients with histologically confirmed chronic GVHD
than in those without it (16.2% vs 32.2%; RR, 0.75;
95%CI, 0.61-0.92; P5 .016) (Figure 2). These results
were confirmed using logistic regression adjusted by
sex, age, donor type, progenitor cell source, sex mis-
match, and type of conditioning regimen (OR, 2.59;
95% CI, 1.12-5.96; P 5 .025), but not when adjusted
by GVHD prophylaxis.
Table 1. Baseline Characteristics of the Study Group
Number of patients 197
Sex, n (%)
Men 114 (57.9)
Women 83 (42.1)
Age, years, mean (SD) 45.3 (14.0)
Type of donor, n (%)
Related 130 (69.5)
Unrelated 51 (27.3)
Others 6 (3.2)
Source of progenitor cells, n (%)
Peripheral blood 155 (83.3)
Bone marrow 31 (16.7)
Type of conditioning, n (%)
Reduced intensity 118 (61.5)
Myeloablative 74 (38.5)
ATG 5 (2.5)
Campath 2 (1)
TBI (myeloablative) 17(23)
Donor–recipient sex mismatch, n (%) 72 (42.4)
GVHD prophylaxis, n (%)
CSA/tacrolimus + MTX 142 (80.2)
CSA/tacrolimus + MMF 22 (12.4)
Others 13 (7.4)
Endoscopic studies, n 379
Gastroscopy, n (%) 338 (89.2)
First 100 days, n (%) 223 (66.0)
Days after transplantation, mean (SD) 41 (24.0)
After 100 days, n (%) 115 (34.0)
Days after transplantation, mean (SD) 269 (210.0)
ATG indicates antithymocyte globulin; CSA, cyclosporine; MMF, myco-
phenolate mofetil; MTX, methotrexate; SD, standard deviation; TBI,
total body irradiation.
Figure 1. Incidence of HP infection among patients with and without
acute GVHD.
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GVHD, the detection of HP in the biopsy specimens
obtained within the first 100 days post-HSCT was
related to a significantly lower risk for the subsequent
development of chronic GVHD. In this regard, we
found that 21.7% of the patients with HP infection de-
veloped chronic GVHD, compared with 52.2% of
HP-negative patients (RR, 0.73; 95% CI, 0.58-0.93;
P 5 .011). Multivariate logistic regression analysis
confirmed this association when adjusted by sex, age,
donor type, progenitor cell source, and type of condi-
tioning regimen (OR, 3.87; 95% CI, 1.25-11.94;
P 5 .018) and by GVHD prophylaxis (OR, 3.45;
95% CI, 1.10-10.83; P 5 .034).Table 2. Frequency and Severity of GVHD
Overall GVHD, n (%) 182 (92.4)
Acute GVHD, n (%) 137 (75.2)
GI GVHD 97 (70.8)
Grade I 23 (23.7)
Grade II 56 (57.7)
Grade III 15 (15.4)
Grade IV 3 (3.1)
Cutaneous GVHD 52 (38)
Liver GVHD 30 (21.9)
Chronic GVHD, n (%) 120 (65.9)
GI GVHD 68 (56.6)
Mild 20 (29.4)
Moderate 36 (53)
Severe 12 (17.6)
Cutaneous GVHD 60 (50.0)
Hepatic GVHD 37 (30.8)Furthermore, HP infection was associated with
significantly lower histological severity (11.1% severe
forms in HP-positive cases vs 88.9% in HP-negative
cases; P5 .003), as indicated by a negative Pearson cor-
relation coefficient (r 5 20.26; P\ .001) (Table 3). In
contrast, we found no significant correlation with endo-
scopic severity according to the classification system of
Cruz-Correa et al. [16].
The overall incidence rate of GVHD was 92.4%
(n 5 182), and HP infection did not affect this rateFigure 2. Incidence of HP infection among patients with and without
chronic GVHD.
Table 3. Relationship between Histological Grade of GI GVHD According to the McDonald and Sales Classification System [17]
and HP Infection
Not Compatible Grade I Grade II Grade III Grade IV
HP-positive, n (% of histological grade) 16 (41.0) 26 (31.0) 4 (9.1) 2 (11.1) 0
HP-negative, n (% of histological grade) 23 (59.0) 58 (69.0) 40 (90.9) 16 (88.9) 0
768 Biol Blood Marrow Transplant 17:765-769, 2011A. Velasco Guardado et al.(P 5 .14). The median follow-up duration was 64.5
months (range, 31.2-108.7 months). A total of 47
patients (23.8%) have died due to nonrelapse mortal-
ity, with a GVHD-related mortality rate of 40.4%
(n 5 19). The rate of response to immunosuppressive
therapy was 77.7% (n 5 153).DISCUSSION
HP stimulates the release of a variety of inflamma-
tory mediators, both directly by bacterial products
and indirectly as a result of interaction with gastric ep-
ithelial cells. These factors allow HP to thrive in
a niche that is inhospitable to almost every other en-
teric organism [18]. Recent epidemiologic studies
have suggested that colonization with HP might
protect against the development of certain autoim-
mune disorders, such as asthma [19,20]. A negative
association between inflammatory bowel disease
(IBD) and HP infection has been established in
numerous studies. A recent meta-analysis of 23 stud-
ies with a total of 5903 patients evaluated the relation-
ship between HP infection and IBD [21]. Thirteen of
the studies noted a significant RR (\1), and no study
found an RR of .1. Some 27% of the patients with
IBD carried an HP infection, compared with an HP
infection rate of 40.9% in the control group. The
authors concluded that these results suggest that HP
infection might have a beneficial effect on the devel-
opment of IBD. Further studies are needed to confirm
this conclusion.
On the other hand, recent laboratory tests have as-
cribed a certain modulating capacity of the immune re-
sponse to HP, with an increased number of regulatory
T cells of the gastric mucosa that might modify the im-
mune response and prevent a Th1/Th17 response
[13,14]. Chen and Blaser [22] suggested that the inten-
sity of the host response against especially aggressive
HP strands (with the cagA gene)might alter the pattern
of the Th1/Th2 immune response, with the subse-
quent induction of immunoregulating lymphocytes
that might prevent immune hyperreactivity responses,
such as asthma or allergy, in cases where the Th2
pattern is predominant.
Two prospective studies of the relationship be-
tween GVHD and HP have been published to date.
The first, by Correia-Silva et al. [23], found no
relationship between HP infection (established on
the basis of polymerase chain reaction analysis ofsaliva) and the development of GVHD in 46 patients
who underwent allogeneic HSCT. The second, by
Au et al. [24], examined the association between HP
infection before transplantation and the subsequent
development of mucositis (drug-related toxicity) and
acute GVHD in 128 patients. No increased risk of mu-
cositis was found in patients with HP colonization;
however, these patients exhibited a significant reduc-
tion in the risk of developing acute GI GVHD (RR,
0.36; 95% CI, 0.13-0.98; P 5 .04). On multivariate
analysis, the absence of HP infection and the presence
of mucositis remained independent predictive factors
of the development of GI GVHD.
In the present study, we found thatHPmay protect
against the development of GVHD, and this effect
remains when we consider patients who have not sus-
tained acute GVHD. Accordingly, HP-positive pa-
tients had a lower risk of acute and chronic GVHD.
It could be argued that gastroscopy was performed
only in patients with GI symptoms, so that in the ab-
sence of acute GVHD, wemight have selected patients
with other concomitant comorbidities, such as HP in-
fection, which could account for these symptoms.
Nevertheless, when we specifically analyzed patients
without acute GVHD, the detection of HP on endos-
copy performed during the first 100 days post-HSCT
significantly decreased the risk of subsequent chronic
GVHD. These results are consistent with the negative
correlation observed between HP infection and histo-
logical severity. Type of conditioning and donor, pro-
genitor cell source, and type of GVHD prophylaxis
were not confounding variables in the association
between GVHD and HP.
This study has some limitations, including its ret-
rospective nature and the fact thatHP infection was di-
agnosed after the onset of symptoms. The standard
hematoxylin and eosin stain is excellent for identifying
histologically chronic or chronic active inflammation
and demonstrates HP when large numbers of bacteria
are present. Silver staining is better at detecting the
organism when few bacteria are present, but does not
optimally demonstrate tissue histology. The best ap-
proach is a combination of hematoxylin and eosin
and Diff-Quick (Newark, Delaware) stain; thus, we
likely underestimated the incidence of HP [25].
To the best of our knowledge, this is the first study
to suggest that HP infection might have a protective
effect against acute and chronic GVHD. Further
prospective studies to evaluate the presence of HP
before transplantation (urea breath test) and the
Biol Blood Marrow Transplant 17:765-769, 2011 769H pylori Infection and GVHDrelationship between CagA strands with the subse-
quent development of GVHD are merited.ACKNOWLEDGMENTS
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